Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome

Iurlo, Alessandra; Nobili, Alessandro; Latagliata, Roberto; Bucelli, Cristina; Castagnetti, Fausto; Breccia, Massimo; Abruzzese, Elisabetta; Cattaneo, Daniele; Fava, Carmen; Ferrero, Dario; Gozzini, Antonella; Bonifacio, Massimiliano; Tiribelli, Mario; Pregno, Patrizia; Stagno, Fabio; Vigneri, Paolo; Annunziata, Mario; Cavazzini, Francesco; Binotto, Gianni; Mansueto, Giovanna; Russo, Sabina; Falzetti, Franca; Montefusco, Enrico; Gugliotta, Gabriele; Storti, Sergio; D'Addosio, Ada M; Scaffidi, Luigi; Cortesi, Laura; Cedrone, Michele; Rossi, Antonella Russo; Avanzini, Paolo; Mauro, Endri; Spadea, Antonio; Celesti, Francesca; Giglio, Gianfranco; Isidori, Alessandro; Crugnola, Monica; Calistri, Elisabetta; Sorà, Federica; Rege Cambrin, Giovanna; Sica, Simona; Luciano, Luigiana; Galimberti, Sara; Orlandi, Ester M; Bocchia, Monica; Tettamanti, Mauro; Alimena, Giuliana; Saglio, Giuseppe; Rosti, Gianantonio; Mannucci, Pier Mannuccio; Cortelezzi, Agostino

doi:10.18632/oncotarget.11657

About 40% of all patients with chronic myeloid leukemia are currently old or very old. They are effectively treated with imatinib, even though underrepresented in clinical studies. Furthermore, as it happens in the general population, they often receive multiple drugs for associated chronic illnesses. Aim of this study was to assess whether or not in imatinib-treated patients aged >75 years the exposure to polypharmacy (5 drugs or more) had an impact on cytogenetic and molecular response rates, event-free and overall survival, as well as on hematological or extra-hematological toxicity.

Scheda prodotto non validato

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Titolo:	Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome
Autori:	Iurlo, Alessandra Nobili, Alessandro Latagliata, Roberto Bucelli, Cristina Castagnetti, Fausto Breccia, Massimo Abruzzese, Elisabetta Cattaneo, Daniele Fava, Carmen Ferrero, Dario Gozzini, Antonella Bonifacio, Massimiliano Tiribelli, Mario Pregno, Patrizia Stagno, Fabio Vigneri, Paolo Annunziata, Mario CAVAZZINI, Francesco Binotto, Gianni Mansueto, Giovanna Russo, Sabina Falzetti, Franca Montefusco, Enrico Gugliotta, Gabriele Storti, Sergio D'Addosio, Ada M Scaffidi, Luigi Cortesi, Laura Cedrone, Michele Rossi, Antonella Russo Avanzini, Paolo Mauro, Endri Spadea, Antonio Celesti, Francesca Giglio, Gianfranco Isidori, Alessandro Crugnola, Monica Calistri, Elisabetta Sorà, Federica Rege Cambrin, Giovanna Sica, Simona Luciano, Luigiana Galimberti, Sara Orlandi, Ester M Bocchia, Monica Tettamanti, Mauro Alimena, Giuliana Saglio, Giuseppe Rosti, Gianantonio Mannucci, Pier Mannuccio Cortelezzi, Agostino mostra contributor esterni nascondi contributor esterni
Data di pubblicazione:	2016
Rivista:	ONCOTARGET
Abstract:	About 40% of all patients with chronic myeloid leukemia are currently old or very old. They are effectively treated with imatinib, even though underrepresented in clinical studies. Furthermore, as it happens in the general population, they often receive multiple drugs for associated chronic illnesses. Aim of this study was to assess whether or not in imatinib-treated patients aged >75 years the exposure to polypharmacy (5 drugs or more) had an impact on cytogenetic and molecular response rates, event-free and overall survival, as well as on hematological or extra-hematological toxicity.
Handle:	http://hdl.handle.net/11392/2364693
Appare nelle tipologie:	03.1 Articolo su rivista

File in questo prodotto:

Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

CINECA IRIS Institutional Research Information System

Scheda prodotto non validato

File in questo prodotto: